Together with the molecular findings from the analysis of canine lymphoma samples [23], these results also suggest the opportunity to investigate the potential clinical utility of targeting P-gp to improve therapeutic efficacy in canine and human patients with MDR to cytostatic agents. Here, PGP is linked to lymphoma.